A homogeneous high-DAR antibody–drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides

The antibody–drug conjugate (ADC) is a well-validated modality for the cell-specific delivery of small molecules with impact expanding rapidly beyond their originally-intended purpose of treating cancer. However, antibody-mediated delivery (AMD) remains inefficient, limiting its applicability to tar...

Descripción completa

Detalles Bibliográficos
Autores principales: Zacharias, Neelie, Podust, Vladimir N., Kajihara, Kimberly K., Leipold, Douglas, Del Rosario, Geoffrey, Thayer, Desiree, Dong, Emily, Paluch, Maciej, Fischer, David, Zheng, Kai, Lei, Corinna, He, Jintang, Ng, Carl, Su, Dian, Liu, Luna, Masih, Shabkhaiz, Sawyer, William, Tinianow, Jeff, Marik, Jan, Yip, Victor, Li, Guangmin, Chuh, Josefa, Morisaki, J. Hiroshi, Park, Summer, Zheng, Bing, Hernandez-Barry, Hilda, Loyet, Kelly M., Xu, Min, Kozak, Katherine R., Phillips, Gail Lewis, Shen, Ben-Quan, Wu, Cong, Xu, Keyang, Yu, Shang-Fan, Kamath, Amrita, Rowntree, Rebecca K., Reilly, Dorothea, Pillow, Thomas, Polson, Andrew, Schellenberger, Volker, Hazenbos, Wouter L. W., Sadowsky, Jack
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926172/
https://www.ncbi.nlm.nih.gov/pubmed/35414872
http://dx.doi.org/10.1039/d1sc05243h

Ejemplares similares

Ejemplares similares